Founded in 1998, the Company is a research and development company, engaged in researching drugs that would help to cure Parkinson’s disease and related complications and diseases. For its research purposes, the Company cooperates with numerous research institutions and receives regular financial support from the Ministry of Finance of Estonia / Enterprise Estonia (EAS).

In June 2024, the Company got approved EAS financial support of EUR 1.6 million to develop an innovative treatment for Amyotrophic lateral sclerosis, Retinitis pigmentosa, and Inflammatory bowel disease. For the research and development works, the Company cooperates with the University of Helsinki which is the main expense of the Company to execute the development project. Once per quarter, the Company can request EAS to cover the funds for paid invoices for the eligible costs of the project; however, first, the Company has to cover costs by itself.

Therefore, the Company is seeking EUR 358,200 financing for 3 months to cover the supplier’s invoices for research and studies. The loan will carry a 15% annual interest rate (1.25% monthly) and it will be amortized at the end of the term from the EAS support funds the Company will reimburse by the end of the year. A personal guarantee from the management board member and a related holding company with an equity capital of EUR 1.5 million will be provided. 

The Company and the board member are repeat clients of Capitalia with excellent payment discipline, having repaid 5 loans for a total amount of EUR 889,269 under a similar settlement scheme. The project risk rate is C (71 out of 100).

The minimum amount of this project is EUR 200,000 in order to conclude the transaction. An additional financing tranche might be published to fundraise the rest of the total approved financing limit of EUR 358,200.

There are a number of factors that make lending to the Company an attractive opportunity and the main highlights are as follows:

• The Company has 26 years of experience in the biotechnology research industry.
• The repayment is linked to a pre-agreed grant from Enterprise Estonia.
• A personal guarantee from the management board member and a related company is provided.
• The Company is a repeat client of Capitalia with excellent payment discipline and has repaid 5 loans with no delays.
• The Company has a significant equity-to-assets ratio of 86%.
• In July 2023 the Company got approved EUR 16 million grant and equity financing from the European Innovation Council Accelerator and the first reimbursement was received in November 2023.